Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 63.18 kCr |
| Price/Earnings (Trailing) | 79.88 |
| Price/Sales (Trailing) | 3.68 |
| EV/EBITDA | 21.15 |
| Price/Free Cashflow | 24.86 |
| MarketCap/EBT | 91.94 |
| Enterprise Value | 74.82 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 17.15 kCr |
| Rev. Growth (Yr) | 11.3% |
| Earnings (TTM) | 629.6 Cr |
| Earnings Growth (Yr) | -163.9% |
Profitability | |
|---|---|
| Operating Margin | 6% |
| EBT Margin | 4% |
| Return on Equity | 1.9% |
| Return on Assets | 1% |
| Free Cashflow Yield | 4.02% |
Growth & Returns | |
|---|---|
| Price Change 1W | 1.5% |
| Price Change 1M | 5.2% |
| Price Change 6M | 11.9% |
| Price Change 1Y | 25% |
| 3Y Cumulative Return | 19.4% |
| 5Y Cumulative Return | 0.00% |
| 7Y Cumulative Return | 3% |
| 10Y Cumulative Return | 17.4% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -234.1 Cr |
| Cash Flow from Operations (TTM) | 4.06 kCr |
| Cash Flow from Financing (TTM) | -1.85 kCr |
| Cash & Equivalents | 4.27 kCr |
| Free Cash Flow (TTM) | 1.92 kCr |
| Free Cash Flow/Share (TTM) | 14.4 |
Balance Sheet | |
|---|---|
| Total Assets | 62.76 kCr |
| Total Liabilities | 29.7 kCr |
| Shareholder Equity | 33.06 kCr |
| Current Assets | 18.78 kCr |
| Current Liabilities | 16.25 kCr |
| Net PPE | 8.86 kCr |
| Inventory | 5.78 kCr |
| Goodwill | 17.46 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.25 |
| Debt/Equity | 0.48 |
| Interest Coverage | -0.29 |
| Interest/Cashflow Ops | 5.33 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 0.5 |
| Dividend Yield | 0.13% |
| Shares Dilution (1Y) | 35% |
| Shares Dilution (3Y) | 35% |
Technicals: Bullish SharesGuru indicator.
Past Returns: In past three years, the stock has provided 19.4% return compared to 13.3% by NIFTY 50.
Size: It is among the top 200 market size companies of india.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Insider Trading: Significant insider selling noticed recently.
Dilution: Company has been diluting it's stock to raise money for business.
Technicals: Bullish SharesGuru indicator.
Past Returns: In past three years, the stock has provided 19.4% return compared to 13.3% by NIFTY 50.
Size: It is among the top 200 market size companies of india.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Insider Trading: Significant insider selling noticed recently.
Dilution: Company has been diluting it's stock to raise money for business.
Investor Care | |
|---|---|
| Dividend Yield | 0.13% |
| Dividend/Share (TTM) | 0.5 |
| Shares Dilution (1Y) | 35% |
| Earnings/Share (TTM) | 4.88 |
Financial Health | |
|---|---|
| Current Ratio | 1.16 |
| Debt/Equity | 0.48 |
Technical Indicators | |
|---|---|
| RSI (14d) | 86.49 |
| RSI (5d) | 92.96 |
| RSI (21d) | 70.48 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Sell |
| RSI5 Signal | Sell |
| RSI21 Signal | Sell |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 5, 2025
Biocon Ltd. shares fell by 1.06% on Friday, with a 14% decline observed in 2025.
Biocon's current share price is Rs 317.7, reflecting a total return of just 2.14% over the past year, while down 14.75% over the last three years.
The stock has seen a return of -0.51% today and is down -5.63% in the past month.
Summary of Biocon's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Biocon Limited's management provided a positive outlook during the Q3 FY26 earnings call, emphasizing the strategic transformation following the acquisition of Viatris' biosimilars business. This transaction valued Biocon Biologics at USD 5.5 billion and is expected to strengthen growth, operational synergies, and long-term value. Key highlights from management include:
Market Positioning: Biocon is positioned at the intersection of fast-growing segments, such as interchangeable biosimilar insulins and GLP-1 peptides. Management indicated that the biosimilars pipeline also includes new oncology and immunology products.
Financial Performance: In Q3 FY26, operating revenue reached INR 4,173 crores, reflecting a 9% year-on-year growth. The core EBITDA was INR 1,221 crores with a margin of 29%. Reported net profit for the quarter was INR 144 crores, and for the first nine months of FY26, operating revenues grew by 14% and EBITDA by 24%.
Biosimilar Growth: The biosimilars division reported revenues of INR 2,497 crores, a 9% year-on-year increase, with an EBITDA of INR 700 crores (up 44% YoY). Management highlighted strong market performance in North America, particularly for products like Yesintek® (biosimilar ustekinumab).
Earnings Upgrades: S&P upgraded Biocon Biologics' rating to BB+ with a stable outlook, while Fitch revised its outlook to positive, indicating sustained earnings momentum and improved financials.
Cost Management: Management highlighted projected annual savings of approximately INR 300 crores in interest costs from FY27 due to debt reduction efforts, which included raising nearly $1 billion and retiring structured debt.
Forward-Looking Statements: Expectations for product launches and growth in the biosimilars and generics market were discussed, indicating management's confidence in future performance amidst a recovering economic landscape.
Biocon remains focused on integrating its operations, enhancing cash flow, and setting the stage for sustainable growth in the coming years.
Understand Biocon ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| KIRAN MAZUMDAR SHAW | 29.9% |
| GLENTEC INTERNATIONAL | 14.63% |
| SBI ARBITRAGE OPPORTUNITIES FUND | 6.99% |
| MYLAN INC. | 5.67% |
| LICI CHILD FORTUNE PLUS GROWTH FUND | 3.85% |
| SERUM INSTITUTE LIFE SCIENCES PRIVATE LIMITED | 3.42% |
| ICICI PRUDENTIAL EQUITY ARBITRAGE FUND | 2.59% |
Detailed comparison of Biocon against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.17 LCr | 58.94 kCr | +7.80% | +5.40% | 38.18 | 7.07 | - | - |
| DIVISLAB | Divi's Lab | 1.7 LCr |
Comprehensive comparison against sector averages
BIOCON metrics compared to Pharmaceuticals
| Category | BIOCON | Pharmaceuticals |
|---|---|---|
| PE | 80.91 | 34.72 |
| PS | 3.73 | 4.79 |
| Growth | 7.1 % | 10.8 % |
Biocon is a prominent Pharmaceuticals company with the stock ticker BIOCON.
The company boasts a market capitalization of Rs. 38,521.3 Crores and was incorporated in 1978. Its headquarters is located in Bengaluru, India. Biocon engages in the manufacture and sale of biotechnology products as well as research services, operating not just in India but also in Brazil, Singapore, and across the globe.
Biocon functions through four primary segments:
The company's product offerings include a variety of generic formulations and API products, targeting areas such as anti-diabetics, immunosuppressants, multiple sclerosis, and oncology. Additionally, it has developed novel biologics products, including a head and neck cancer molecule and psoriasis molecules. Its biosimilars portfolio includes insulins, trastuzumab, pegfilgrastim, and bevacizumab.
Biocon also provides integrated discovery, development, and manufacturing services to a diverse range of sectors, including pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemicals.
In the past year, Biocon has reported a trailing revenue of Rs. 16,012.2 Crores, demonstrating an impressive revenue growth of 99.7% over the last three years. The company also offers a dividend to its investors, with a yield of 0.52% per year and a recent dividend payout of Rs. 2 per share.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
BIOCON vs Pharmaceuticals (2021 - 2026)
Biocon Biologics has secured multiple market access agreements for its biosimilar Yesintek, covering over 100 million lives in the US.
Investor Presentation • 25 Feb 2026 Investor Presentation |
Press Release / Media Release • 24 Feb 2026 Press Release |
Analyst / Investor Meet • 17 Feb 2026 Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s) |
Earnings Call Transcript • 17 Feb 2026 Transcript of Earnings call Q3 FY26 |
Newspaper Publication • 14 Feb 2026 Newspaper Publication |
Analyst / Investor Meet • 13 Feb 2026 Audio and Video Recording of Q3 FY26 Earnings Call |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
1. Question: "First question on the biosimilar business, the upgrade of production and quality that you have mentioned, is it fair to assume that this is largely done and behind us? What led to this need for this upgradation of production?"
Answer: Yes, we're nearing completion of our upgrades. The need stemmed from the substantial demand for our products and upcoming launches across various markets. This was a planned operation to enhance our scalability. We believe this positions us for continued growth while maintaining high margins, which exceeded our guidance.
2. Question: "How should we think about growth from here, given we have a bunch of these launches?"
Answer: While I won't provide specific guidance, we've seen strong growth historically. With recent launches and increasing demand, we anticipate growth in the biosimilar business and a potential improvement in margins. The trajectory looks promising as our product pipeline matures.
3. Question: "Can you help us through what the capex would look like for the consolidated entity in fiscal '26 and '27?"
Answer: Our capex is moderating, declining from over $275 million to below $225 million. Most of the heavy investment is behind us, focusing now primarily on doubling our insulin capacity, with only maintenance capex thereafter.
4. Question: "Can you help us understand your other operating expense during the quarter?"
Answer: The operating expenses were roughly INR 1,178 crores, largely fixed in nature. Growth in this line will be lower than revenue growth henceforth, as much of the base spending is already established.
5. Question: "What is your rationale behind acquiring the full global rights for Hulio (adalimumab)?"
Answer: Hulio has been a successful franchise, generating over $200 million annually. Acquiring full rights allows us to have greater control and to fully integrate and expand our offerings in the onco-immunology segment.
6. Question: "What are the drivers for revenue growth in the biologics business?"
Answer: We've maintained year-on-year growth, driven by our diverse product launches and increasing demand. New products are gaining traction, particularly Yesintek in the U.S., which is expected to boost revenue in the coming quarters.
7. Question: "Can you provide an update on the GLP-1s and semaglutide in Canada?"
Answer: We've filed for GLP-1 approvals in several markets, including Canada. The regulatory process is complex, with no approvals yet; however, we're confident that our comprehensive development capabilities will see successful outcomes in the future.
8. Question: "Will the insulin demand remain strong given market trends?"
Answer: Demand for insulin remains robust. We're well-positioned with significant manufacturing capabilities and expect to grow our market share, especially as we double our drug product capacity in the upcoming fiscal year.
9. Question: "Could you clarify the EBITDA of INR 700 crores in the biosimilars business?"
Answer: Yes, this figure is clean EBITDA, with no exceptional gains included. We've focused on prioritizing high-margin markets, which contributed to improved margins despite the overall revenue decline in this period.
10. Question: "Can you share market share information for existing vs. new products?"
Answer: While specific quarter-by-quarter breakdowns are difficult, existing products continue to hold strong market shares, with new launches expected to ramp up and contribute significantly to our overall growth as we move into fiscal '27.
| KOTAK LARGE & MIDCAP FUND | 1.31% |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA | 1.25% |
| MIRAE ASSET NIFTY MIDCAP 150 ETF | 1.19% |
| ACTIV PINE LLP | 1.09% |
| BENEFICIAL HOLDINGS UNDER MGT-4 | 0.34% |
| RAVI RASENDRA MAZUMDAR | 0.33% |
| DEV MAZUMDAR | 0.06% |
| Glenloch Properties LLP | 0% |
| Mazumdar Shaw Medical Foundation | 0% |
| Carica Investment | 0% |
| Jeeves | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.75 kCr |
| +3.60% |
| +14.10% |
| 68.64 |
| 15.82 |
| - |
| - |
| CIPLA | Cipla | 1.09 LCr | 29.37 kCr | +1.30% | -6.60% | 23.91 | 3.7 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.07 LCr | 36.09 kCr | +5.20% | +14.30% | 19.24 | 2.97 | - | - |
| LUPIN | Lupin | 1.05 LCr | 26.49 kCr | +8.10% | +21.70% | 22.63 | 3.97 | - | - |
| AUROPHARMA | Aurobindo Pharma | 70.88 kCr | 33.73 kCr | +7.10% | +12.90% | 20.33 | 2.1 | - | - |
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
| -3.3% |
| 4,065 |
| 4,205 |
| 3,925 |
| 3,988 |
| 3,718 |
| 3,550 |
| Profit Before exceptional items and Tax | 23.6% | 226 | 183 | 97 | 466 | 138 | 72 |
| Exceptional items before tax | -2182.2% | -293.4 | -11.9 | 0 | 20 | 18 | 26 |
| Total profit before tax | -140.5% | -67.8 | 171 | 97 | 487 | 156 | 98 |
| Current tax | 13.8% | 67 | 59 | 67 | 6.1 | 114 | 24 |
| Deferred tax | -285.3% | -83 | -20.8 | -59 | 21 | -38.8 | 47 |
| Total tax | -145.9% | -16 | 38 | 7.7 | 27 | 75 | 71 |
| Total profit (loss) for period | -140% | -51.8 | 133 | 89 | 459 | 81 | 27 |
| Other comp. income net of taxes | -68.5% | 306 | 970 | -205.5 | -183.8 | 57 | 522 |
| Total Comprehensive Income | -77% | 254 | 1,103 | -116.3 | 276 | 138 | 549 |
| Earnings Per Share, Basic | 123.5% | 1.08 | 0.66 | 0.26 | 2.88 | 0.21 | -0.13 |
| Earnings Per Share, Diluted | 120% | 1.07 | 0.65 | 0.26 | 2.87 | 0.21 | -0.13 |
| 10.9% |
| 501 |
| 452 |
| 434 |
| 368 |
| 390 |
| 345 |
| Finance costs | 19.2% | 237 | 199 | 70 | 0.4 | 0.4 | 1.2 |
| Depreciation and Amortization | 5.8% | 128 | 121 | 117 | 108 | 104 | 98 |
| Other expenses | 11.9% | 535 | 478 | 551 | 501 | 527 | 530 |
| Total Expenses | 11.4% | 2,432 | 2,184 | 2,156 | 1,786 | 1,820 | 1,802 |
| Profit Before exceptional items and Tax | -61.5% | 53 | 136 | 108 | 140 | 359 | 388 |
| Exceptional items before tax | 4569.2% | 608 | 14 | 2,863 | 0 | 0 | 160 |
| Total profit before tax | 343% | 661 | 150 | 2,971 | 140 | 359 | 548 |
| Current tax | 114.3% | 31 | 15 | 123 | 54 | 78 | 112 |
| Deferred tax | 33.3% | 21 | 16 | 0 | 0 | 0 | 0 |
| Total tax | 70% | 52 | 31 | 123 | 54 | 78 | 112 |
| Total profit (loss) for period | 415.3% | 609 | 119 | 2,848 | 86 | 280 | 441 |
| Other comp. income net of taxes | -688.2% | -12.4 | -0.7 | 0.9 | 8 | 2.4 | -7.7 |
| Total Comprehensive Income | 405.1% | 597 | 119 | 2,849 | 94 | 283 | 433 |
| Earnings Per Share, Basic | - | 5.09 | 1 | 23.87 | 0.72 | 2.36 | 3.72 |
| Earnings Per Share, Diluted | - | 5.09 | 1 | 23.82 | 0.72 | 2.34 | 3.71 |
| 19.7% |
| 822 |
| 687 |
| 579 |
| 545 |
| 464 |
| 329 |
| Investment property | -3.8% | 52 | 54 | 56 | 58 | 60 | 62 |
| Goodwill | - | 0 | 0 | 38 | 0 | 0 | 0 |
| Non-current investments | 16.7% | 13,285 | 11,383 | 10,038 | 9,256 | 9,144 | 8,950 |
| Loans, non-current | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total non-current financial assets | 15.2% | 13,305 | 11,548 | 10,062 | 9,410 | 9,293 | 9,093 |
| Total non-current assets | 14.6% | 15,418 | 13,451 | 11,990 | 11,008 | 10,801 | 10,464 |
| Total assets | 26.9% | 19,821 | 15,621 | 14,170 | 13,768 | 13,682 | 13,030 |
| Borrowings, non-current | -96.1% | 89 | 2,252 | 2,131 | 2,041 | 1,919 | 1,298 |
| Total non-current financial liabilities | -95.9% | 93 | 2,255 | 2,154 | 2,064 | 1,936 | 1,318 |
| Provisions, non-current | 25% | 41 | 33 | 32 | 28 | 28 | 25 |
| Total non-current liabilities | -90.9% | 215 | 2,360 | 2,264 | 2,165 | 2,030 | 1,416 |
| Borrowings, current | 295.6% | 2,450 | 620 | 52 | 0 | 0 | 0 |
| Total current financial liabilities | 119.4% | 3,443 | 1,570 | 837 | 527 | 641 | 543 |
| Provisions, current | 12.1% | 38 | 34 | 35 | 32 | 30 | 28 |
| Current tax liabilities | 1% | 107 | 106 | 102 | 101 | 100 | 97 |
| Total current liabilities | 108.6% | 3,623 | 1,737 | 1,016 | 691 | 800 | 698 |
| Total liabilities | -6.3% | 3,838 | 4,097 | 3,280 | 2,856 | 2,830 | 2,114 |
| Equity share capital | 11.4% | 668 | 600 | 600 | 600 | 600 | 600 |
| Total equity | 38.7% | 15,983 | 11,524 | 10,890 | 10,912 | 10,852 | 10,916 |
| Total equity and liabilities | 26.9% | 19,821 | 15,621 | 14,170 | 13,768 | 13,682 | 13,030 |
| 96.5% |
| 0 |
| -27.4 |
| -49.5 |
| 0 |
| - |
| - |
| Interest received | 98.5% | 0 | -65.7 | 0 | 0 | - | - |
| Income taxes paid (refund) | 55.6% | 43 | 28 | 41 | 28 | - | - |
| Net Cashflows From Operating Activities | 599.2% | 621 | -123.2 | 219 | 48 | - | - |
| Cashflows used in obtaining control of subsidiaries | - | 0 | 0 | 4,071 | 0 | - | - |
| Proceeds from sales of PPE | -433.3% | 0 | 1.3 | 2.6 | 2.1 | - | - |
| Purchase of property, plant and equipment | 5% | 317 | 302 | 262 | 239 | - | - |
| Purchase of investment property | - | 0 | 0 | 0 | 1,106 | - | - |
| Purchase of intangible assets | -16.3% | 4.6 | 5.3 | 4.9 | 7.5 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | - | 0 | 0 | 22 | 3 | - | - |
| Dividends received | 11.5% | 30 | 27 | 50 | 0 | - | - |
| Interest received | 7.3% | 45 | 42 | 46 | 28 | - | - |
| Other inflows (outflows) of cash | 7.8% | 607 | 563 | -375.8 | 1,110 | - | - |
| Net Cashflows From Investing Activities | -232.9% | -989 | -296.4 | -1,177.8 | -305.6 | - | - |
| Payments to acquire or redeem entity's shares | - | 0 | 0 | 65 | 0.3 | - | - |
| Proceeds from exercise of stock options | -70.3% | 9.9 | 31 | 30 | 43 | - | - |
| Proceeds from issuing debt | - | 0 | 0 | 1,070 | 0 | - | - |
| Proceeds from borrowings | 11.6% | 558 | 500 | 2,632 | 73 | - | - |
| Repayments of borrowings | - | 0 | 0 | 2,515 | 0.7 | - | - |
| Payments of lease liabilities | 333.3% | 2.3 | 1.3 | 0 | 0 | - | - |
| Dividends paid | -67% | 60 | 180 | 60 | 0 | - | - |
| Interest paid | 112.8% | 11 | 5.7 | 51 | 1.4 | - | - |
| Net Cashflows from Financing Activities | 44% | 495 | 344 | 1,039 | 112 | - | - |
| Effect of exchange rate on cash eq. | -200% | 0.3 | 1.7 | 4.7 | 3.5 | - | - |
| Net change in cash and cash eq. | 267.3% | 127 | -74.3 | 86 | -142.5 | - | - |
Investor Presentation • 13 Feb 2026 Investor Presentation |
Analysis of Biocon's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Biosimilars | 58.5% | 2.5 kCr |
| CRDMO | 21.5% | 917.1 Cr |
| Generics | 20.0% | 851.3 Cr |
| Total |
| 4.3 kCr |